Field flow fractionation of proteins, macromolecules and nanoparticles
The Postnova AF2000 MultiFlow reported to offer more flexibility, better performance and more robust results than any system before.
The Postnova AF2000 MultiFlow is a high performance Flow Field-Flow Fractionation (FFF) platform for separation of proteins, macromolecules and nanoparticles.
Modular in design, the AF2000 MultiFlow incorporates the combined experience, expertise and technological advances from Postnova Analytics' nearly two decades of leadership in FFF. Incorporating a range of FFF modules in a single integrated system to provide universal separation, the AF2000 MultiFlow offers more flexibility, better performance and more robust results than any system before.
The AF2000 MultiFlow platform is based on the Flow FFF principles using a unique crossflow field design in which samples are separated by their dynamic diffusion on the basis of molar mass or particle size. Because of this design and the absence of any stationary phase, field-flow fractionation on the AF2000 MultiFlow can be performed without exerting shear forces and stress on the molecules or particles being separated.
The AF2000 can be run with different eluents, wide ranging temperature conditions and the same system can be used for running planar Asymmetric Flow FFF (AF4) or circular Hollow Fiber Flow FFF separations (HF5). Consequently, the AF2000 MultiFlow is an ideal platform for the characterization of proteins, antibodies, aggregates, vaccines, VLPs, liposomes, nanoparticles and natural or synthetic polymers.
The AF2000 MultiFlow is available in a series of different models. Various add-on modules, extra options and special FFF detectors are available, such as Multi-Angle Light Scattering (MALS) and Dynamic Light Scattering (DLS). All Postnova FFF modules and detectors have been especially developed for FFF and are perfectly optimised not only for the use with the AF2000 MultiFlow, but also for the other Postnova FFF systems. Additionally, the AF2000 Series has been designed for easy interfacing with high-end detection technologies, such as ICP-MS, from other suppliers that may already be at use in laboratories.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance